TEVA•benzinga•
Goldman Sachs Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $24
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 6, 2025 by benzinga